Evaluation of the molecular effects of metformin and improvement of symptoms in osteoarthritis patients

Evaluation of interaction of mTOR signaling pathway and improvement of symptoms in osteoarthritis patients treated with metformin

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150202020908N2

Enrollment

100

Registered

2020-12-24

Start date

2019-06-22

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Osteoarthritis patients with high-BMI who take metformin in addition to their previous treatment. In the first week, 500 mg daily, the second week 1000 mg daily and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Obesity Inflammatory osteoarthritis

Exclusion criteria

Exclusion criteria: Autoimmune disease Age under 18 years old Cancer Inflammatory bowel disease Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
WOMAC questionnaire score. Timepoint: At the beginning of the study (before the intervention) and 16 weeks after starting metformin. Method of measurement: WOMAC questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Tahami

Shiraz University of Medical Sciences

mohammad.tahami@yahoo.com+98 71 3623 4504

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026